keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg seroconversion

keyword
https://www.readbyqxmd.com/read/29327822/efficacy-and-safety-of-long-term-entecavir-therapy-in-a-european-population
#1
Alessandro Collo, Paola Belci, Sharmila Fagoonee, Lucia Loreti, Valeria Gariglio, Ramona Parise, Paola Magistroni, Marilena Durazzo
BACKGROUND: Therapy in chronic hepatitis B (CHB) patients aims at improving their survival by preventing disease progression to cirrhosis and its complications. Entecavir (ETV) is currently a first line therapeutic agent recommended for the treatment of CHB. Our aim was to evaluate the long term outcome of a cohort of CHB patients treated with ETV. METHODS: Thirty-four patients treated with ETV for at least 6 months were included in this study. The virologic response was determined by the dosage of serum HBV-DNA, HBsAg, HBeAg, anti-HBs and anti-HBe antibodies...
January 10, 2018: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29315352/hepatitis-b-infection-among-hiv-infected-individuals-in-gabon-occult-hepatitis-b-enhances-hbv-dna-prevalence
#2
Berthold Bivigou-Mboumba, Marie Amougou-Atsama, Samira Zoa-Assoumou, Hervé M'boyis Kamdem, Guy Francis Nzengui-Nzengui, Angélique Ndojyi-Mbiguino, Richard Njouom, Sandrine François-Souquière
In Gabon, a central African country, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are endemic. In a recent study, conducted in a semi-urban area (Franceville, Gabon), HBV infection was found to be more prevalent among HIV infected individuals. This study aims to investigate the prevalence and genetic diversity of hepatitis B virus infection among HIV infected individuals, predominantly under antiretroviral therapy, living in fully urbanized area: Libreville, capital of Gabon. Serological and molecular tests were performed to detect HBV infection among patients living with HIV/AIDS (PLHA)...
2018: PloS One
https://www.readbyqxmd.com/read/29310589/hepatitis-b-reactivation-among-1962-patients-with-hematological-malignancy-in-taiwan
#3
Chien-Yuan Chen, Feng-Ming Tien, Aristine Cheng, Shang-Yi Huang, Wen-Chien Chou, Ming Yao, Jih-Luh Tang, Hwei-Fang Tien, Wang-Huei Sheng
BACKGROUND: The risk of Hepatitis B virus (HBV) reactivation in patients with different hematological malignancy except lymphoma were rarely known before. METHODS: A total of 1962 patients with hematological malignancy were enrolled and followed-up at the National Taiwan University Hospital between 2008 and 2013. The clinical characteristics, HBV serology, and laboratory data were retrospectively reviewed and analyzed. RESULTS: A total of 1962 patients comprising 1048 men and 914 women were studied...
January 8, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29306503/a-mouse-model-with-age-dependent-immune-response-and-immune-tolerance-for-hbv-infection
#4
Xuerui Yi, Youcheng Yuan, Na Li, Lu Yi, Cuiling Wang, Ying Qi, Liang Gong, Guangze Liu, Xiangping Kong
BACKGROUND: Viral clearance of human HBV infection largely depends on the age of exposure. Thus, a mouse model with age-dependent immune response and immune-tolerance for HBV infection was established. METHODS: HBVRag1 mice were generated by crossing Rag1-/- mice with HBV-Tg mice. Following adoptive transfer of splenocytes adult (8-9 weeks old) and young (3 weeks old) HBVRag1 mice were named as HBVRag-ReA and HBVRag-ReY mice respectively. The biochemical parameters that were associated with viral load and immune function, as well as the histological evaluation of the liver tissues between the two mouse models were detected...
January 3, 2018: Vaccine
https://www.readbyqxmd.com/read/29184389/baracle%C3%A2-vs-baraclude%C3%A2-for-48-weeks-in-patients-with-treatment-na%C3%A3-ve-chronic-hepatitis-b-a-comparison-of-efficacy-and-safety
#5
Do Young Kim, Ju Hyun Kim, Won Young Tak, Jong Eun Yeon, Joon Hyeok Lee, Jung Hwan Yoon, Youn Jae Lee, Byung Seok Lee, Byung Hoon Han, Han Chu Lee
Background and objective: Entecavir (ETV) is a standard of care for chronic hepatitis B (CHB). In a bioequivalence study, ETV from Dong-A ST (Baracle®) was found to have a pharmacokinetic profile equivalent to ETV from Bristol-Myers Squibb (BMS) (Baraclude®). The present study was conducted to evaluate the antiviral activity and safety of ETV from Dong-A ST in comparison to ETV from BMS in patients with CHB. Methods: In this multicenter, double-blind, active-controlled, stratified-randomized, parallel group, comparative trial, 118 treatment-naïve patients with CHB were randomly assigned to receive either 0...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29170915/potential-use-of-serum-hbv-rna-in-antiviral-therapy-for-chronic-hepatitis-b-in-the-era-of-nucleos-t-ide-analogs
#6
REVIEW
Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia
Although the efficacy of nucleos(t)ide analogue (NA) has been confirmed for treatment of chronic hepatitis B, long-term therapy has been recommended due to the high frequency of off-therapy viral DNA rebound and disease relapse. In this review, the RNA virion-like particles of hepatitis B virus (HBV) are integrated into the life cycle of HBV replication, and the potential significance of serum HBV RNA is systematically described. The production of HBV RNA virion-like particles should not be blocked by NA; in this regard, serum HBV RNA is found to be a suitable surrogate marker for the activity of intrahepatic covalently closed circular DNA (cccDNA), particularly among patients receiving NA therapy...
November 23, 2017: Frontiers of Medicine
https://www.readbyqxmd.com/read/29158122/biomarkers-distinguish-hbeag-seroconverted-from-non-converted-individuals-in-chronic-hepatitis-b-patients-treated-with-a-therapeutic-vaccine
#7
Xian Zhou, Shuang Geng, Shijie Zhang, Weidong Zhao, Gan Zhao, Yumei Wen, Xuanyi Wang, Bin Wang
Cytokine assays of host immune responses to vaccination can indicate vaccine efficacy. Here we tested the hypothesis that assays of the cytokine status of infected individuals prior to therapeutic vaccination might provide a guide to vaccine therapeutic efficacy. If so, cytokine analysis might be used to select appropriate patients for therapeutic vaccination. Data were obtained from a panel of 14 cytokine/chemokine assays that were done during a phase III clinical trial of HBsAg-HBIG therapeutic vaccine (YIC) treatment of chronic hepatitis B (CHB) patients...
November 17, 2017: Cytokine
https://www.readbyqxmd.com/read/29131246/study-on-the-distribution-of-cd8-memory-t-cell-subsets-and-ifn-%C3%AE-level-during-the-spontaneous-clearance-of-hepatitis-b-virus-in-patients-with-chronic-hepatitis-b-virus-infection
#8
X-J Ma, X-F Chen, W-L Chen, R Chen, J Huang, X-D Luo, J-Y Liao, X-P Chen
OBJECTIVE: To study the alteration of CD8+ memory T cell subsets under different immune statuses during the spontaneous clearance of hepatitis B virus (HBV) in Chinese patients with chronic HBV infection. PATIENTS AND METHODS: We analyzed Chinese patients with chronic HBV infection including 10 patients with Hepatitis B surface Antigen (HBsAg) spontaneous seroconversion, 25 patients with Hepatitis B virus e Antigen (HBeAg) spontaneous seroconversion, 25 patients with chronic hepatitis B (CHB), and 25 chronic HBV carriers...
October 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29091317/the-change-of-antibody-levels-in-children-changes-and-analysis-of-anti-hbs-titers-after-primary-immunization-in-1-16-year-old-chinese-children-a-hospital-based-study
#9
Xiaomei Yue, Congcong Ge, Shurui Zhuge, Hao He, Hui Yang, Hongmei Xu, Ailong Huang, Yao Zhao
Immunization with the hepatitis B vaccine is the most effective measure to prevent Hepatitis B Virus (HBV) infection. The aim of this study was to investigate the change in antibody levels induced by administration of the hepatitis B vaccine in children aged 1-16 year-old in a large sample sized investigation. HBV markers were determined in 93,326 1-16 year-old hospitalized children who completed primary immunization as infants from southwest China, Chongqing. Analyses were performed on anti-HBs titer changes with increasing age, and the revaccination effect was evaluated in children aged 7-14...
November 1, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082652/long-term-outcome-of-telbivudine-versus-entecavir-in-treating-higher-viral-load-chronic-hepatitis-b-patients-without-cirrhosis
#10
H-Y Pan, H-Y Pan, W-Y Song, W Zheng, Y-X Tong, D-H Yang, Y-N Dai, M-J Chen, M-S Wang, Y-C Huang, J-J Zhang, H-J Huang
Chronic hepatitis B (CHB) patients with higher hepatitis B virus (HBV) load (higher viral load [HVL], HBV DNA ≥1 × 107 copies/mL) require antiviral therapy, but data for evaluating the long-term outcome of this therapy with antiviral agents remain limited. We comparatively evaluated the efficacy and the safety of nucleoside analogues in 179 noncirrhotic CHB patients with HVL over 5 years. The HBeAg-positive (n = 104) or HBeAg-negative (n = 75) patients were treated consecutively with telbivudine (LdT, n = 88) or entecavir (ETV, n = 91) and evaluated for viral response, drug resistance and safety...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082651/comparison-of-208-week-sequential-therapy-with-telbivudine-and-entecavir-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-responses-to-24%C3%A2-weeks-of-peg-ifn%C3%AE-2a-therapy-an-open-labelled-randomized-controlled-real-life-trial
#11
X D Luo, X F Chen, Y Zhou, X P Chen
The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. This was an open-label, randomized, controlled, "real-life" trial. HBeAg-positive CHB patients with serum HBV DNA ≥5.0 lg IU/mL and a < 1 lg IU/mL decline of HBsAg level from baseline who underwent at least 24 weeks of Peg-IFNα-2a therapy were included. Enrolled patients were randomized to receive either telbivudine (600 mg/d, n = 95) or entecavir (0...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082646/safety-and-efficacy-of-telbivudine-for-chronic-hepatitis-b-during-the-entire-pregnancy-long-term-follow-up
#12
J Shang, Q Wen, C C Wang, K Liu, L Bai, H Tang
The management of hepatitis B virus (HBV) infection in pregnancy is a unique issue. Telbivudine (LdT) is recommended to block HBV mother-to-child transmission (MTCT) in the third trimester. However, the safety of LdT treatment during the entire pregnancy for the long-term growth of infants is unclear. The aim of this study was to evaluate the efficacy and long-term safety of LdT for the entire pregnancy period. This retrospective cohort study included 40 pregnant women and 43 children from 2011 to 2017. The antiviral effects and maternal abnormalities were evaluated...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29072673/seven-year-treatment-outcome-of-entecavir-in-a-real-world-cohort-effects-on-clinical-parameters-hbsag-and-hbcrag-levels
#13
Yuk-Fai Lam, Wai-Kay Seto, Danny Wong, Ka-Shing Cheung, James Fung, Lung-Yi Mak, John Yuen, Chun-Kong Chong, Ching-Lung Lai, Man-Fung Yuen
OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related antigen (HBcrAg)); hepatitis B e antigen (HBeAg) seroconversion and drug resistance rates after 7 years of entecavir treatment in chronic hepatitis B (CHB) patients. METHODS: Two hundred and twenty-two Chinese CHB patients on continuous entecavir treatment were recruited. Serologic, virologic, biochemical outcomes, and the occurrence of entecavir signature mutations were determined...
October 26, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/29056008/-clinical-effect-and-safety-of-pegylated-interferon-%C3%AE-2b-injection-y-shape-40-kd-in-treatment-of-hbeag-positive-chronic-hepatitis-b-patients
#14
F Q Hou, Y L Yin, L Y Zeng, J Shang, G Z Gong, C Pan, M X Zhang, C B Yin, Q Xie, Y Z Peng, S J Chen, Q Mao, Y P Chen, Q G Mao, D Z Zhang, T Han, M R Wang, W Zhao, J J Liu, Y Han, L F Zhao, G H Luo, J M Zhang, J Peng, D M Tan, Z W Li, H Tang, H Wang, Y X Zhang, J Li, L L Zhang, L Chen, J D Jia, C W Chen, Z Zhen, B S Li, J Q Niu, Q H Meng, H Yuan, Y T Sun, S C Li, J F Sheng, J Cheng, L Sun, G Q Wang
Objective: To investigate the clinical effect and safety of long-acting pegylated interferon-α-2b (Peg-IFN-α-2b) (Y shape, 40 kD) injection (180 μg/week) in the treatment of HBeAg-positive chronic hepatitis B (CHB) patients, with standard-dose Peg-IFN-α-2a as positive control. Methods: This study was a multicenter, randomized, open-label, and positive-controlled phase III clinical trial. Eligible HBeAg-positive CHB patients were screened out and randomized to Peg-IFN-α-2b (Y shape, 40 kD) trial group and Peg-IFN-α-2a control group at a ratio of 2:1...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29056007/-clinical-effect-of-156-week-telbivudine-sequential-therapy-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-response-to-pegylated-interferon-%C3%AE-2a-therapy
#15
X D Luo, X P Chen, X F Chen
Objective: To investigate the clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a (Peg-IFN-α-2a) therapy. Methods: A total of 35 HBeAg-positive CHB patients with HBV DNA < 500 IU/ml who were treated with Peg-IFN-α-2a for 48 weeks and did not experience seroconversion of HBeAg were given telbivudine sequential therapy for 156 weeks. HBeAg clearance rate, HBeAg seroconversion rate, HBV DNA clearance rate, safety, and drug resistance rate were analyzed...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29055925/clinical-analysis-of-polyethylene-glycol-interferon-%C3%AE-treatment-in-155-hepatitis-b-e-antigen-hbeag-positive-chronic-hepatitis-b-chb-patients
#16
Xin Luo, Ji-Xian Yu, Lei Xie, Wen-Jun Ma, Li-Hong Wang
PURPOSE: This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and 48th week after withdrawal, in order to provide guidance on the antiviral treatment of HBeAg-positive CHB patients. MATERIAL AND METHODS: Antiviral treatment was performed on 155 HBeAg-positive CHB patients. Among these patients, 66 patients received PEG-interferon α-2a treatment and 89 patients received PEG-interferon α-2b treatment; and these treatments were administered by subcutaneous injection, once per week, which lasted for 48 weeks...
October 16, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/29042662/switching-to-pegifn%C3%AE-2b-leads-to-hbsag-loss-in-patients-with-low-hbsag-levels-and-hbv-dna-suppressed-by-nas
#17
Jing Huang, Ka Zhang, Wenli Chen, Jinyao Liao, Xiaodan Luo, Ren Chen
Patients with low hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA suppression by nucleos(t)ide analogues (NAs) achieve high rate of HBsAg loss through switching to PegIFNα in pre-registration study. The aim of this study was to achieve higher rate of HBsAg loss through extended PegIFN treatment. 98 patients with HBsAg < 2,000 IU/ml and HBV DNA < 20 IU/ml were randomized to receive PegIFNα-2b or continuing NA therapy for 60 weeks. At the end of treatment (EOT) and end of follow-up (EOF), only patients who switched to PegIFNα-2b achieved HBsAg loss (32...
October 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29035003/hepatitis-b-core-related-antigen-hbcrag-an-emerging-marker-for-chronic-hepatitis-b-virus-infection
#18
REVIEW
L-Y Mak, D K-H Wong, K-S Cheung, W-K Seto, C-L Lai, M-F Yuen
BACKGROUND: Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non-invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core-related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB...
October 16, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29023803/hbeag-levels-at-week-24-predict-response-to-8%C3%A2-years-of-tenofovir-in-hbeag-positive-chronic-hepatitis-b-patients
#19
D Wong, M Littlejohn, L Yuen, K Jackson, H Mason, J Bayliss, G Rosenberg, A Gaggar, K Kitrinos, M Subramanian, P Marcellin, M Buti, H L A Janssen, E Gane, S Locarnini, A Thompson, P A Revill
BACKGROUND: Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful. AIM: To evaluate the utility of measuring HBeAg levels for predicting HBeAg seroconversion and HBsAg loss under long-term tenofovir (TDF) therapy. METHODS: A total of 266 patients were enrolled into a phase III study of TDF vs adefovir (ADV) for 48 weeks in HBeAg-positive patients, followed by open-label TDF up to 384 weeks...
October 11, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28988797/altered-expression-of-interferon-stimulated-genes-is-strongly-associated-with-therapeutic-outcomes-in-hepatitis-b-virus-infection
#20
Meifang Han, Yong Li, Wenyu Wu, Yuanya Zhang, Weiming Yan, Xiaoping Luo, Qin Ning
Our previous OSST study shows that switching to pegylated interferon (Peg-IFN)-α2a results in higher rates of response hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss at the end of treatment, compared with nucleot(s)ide analogues (NAs) monotherapy in long term NA-treated chronic hepatitis B (CHB) patients. In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study...
October 6, 2017: Antiviral Research
keyword
keyword
31626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"